Novartis's everolimus wins US panel nod for kidney transplant use
This article was originally published in Scrip
Executive Summary
The US FDA's outside experts have endorsed the efficacy and safety of Novartis's kinase inhibitor everolimus for the prevention of kidney transplant rejection.